johnson and johnson

Ortho Ordered to Pay $1.7 Million in Levaquin Lawsuit

On Wednesday, a Minneapolis jury ordered Johnson & Johnson subsidiary Ortho-McNeil-Janssen Pharmaceuticals to pay an 87-year-old man $1.7 million because its antibiotic Levaquin damaged his Achilles tendons. It was the first verdict from about 2,600 similar lawsuits filed so far.

Johnson & Johnson Announces Bid for Crucell

As part of its efforts to expand into the biotech market, Johnson & Johnson is making a long-anticipated bid for Dutch vaccine maker Crucell -- in spite of Crucell's recent manufacturing troubles.

Johnson & Johnson Recalls Mylanta Over Labeling

If you get the feeling Johnson & Johnson is recalling products every day, you wouldn't be that far from the truth. Now it's dragging Merck with it as the two announced a recall of 12 over-the-counter Mylanta heartburn medicine liquid products as well as Alternagel liquid antacid to update product labeling.

Can GE and J&J Help Detect Alzheimer's Earlier?

Medical imaging and diagnostics powerhouse GE Healthcare teams up with pharmaceutical giant Johnson & Johnson to research methods of detecting Alzheimer's in patients -- even before they begin to exhibit symptoms of the devastating disease.

J&J Earnings Hurt by Children's Medicine Recalls

Tylenol and Band-Aid maker Johnson & Johnson announced on Tuesday that its sales declined 0.7% to $15 billion in the third quarter, compared to the same quarter last year, as domestic sales were "significantly impacted" by recent successive recalls. Domestic sales declined 2.5%.

J&J Apologizes for Kids Medicine Issues, Phantom Recalls

In testimony before Congress Thursday, Johnson & Johnson's CEO apologized for the problems that have beset his company, including the quality issues with its children's medicines and the "phantom recall" of a batch of Motrin. He also said new batches of its children's medicines should start shipping next week.

What Buffett's Buying: A Stake in Fiserv, More J&J

The latest quarterly filing from Warren Buffett's Bekshire Hathaway shows what changes the Oracle of Omaha made to his portfolio. What led him to buy into payment processor Fiserv and raise his stake in J&J?